PMID- 27026335
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20220129
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
VI  - 27
IP  - 8
DP  - 2016 Aug
TI  - Response of bone turnover markers to raloxifene treatment in postmenopausal women 
      with osteopenia.
PG  - 2585-92
LID - 10.1007/s00198-016-3573-z [doi]
AB  - We used two methods of identifying women who reached the target for raloxifene 
      treatment with bone turnover markers. Both approaches identified women that 
      responded to treatment but did not fully agree and may be complementary. 
      INTRODUCTION: The change in bone turnover markers (BTMs) in response to 
      osteoporosis therapy can be assessed by a decrease beyond the least significant 
      change (LSC) or below the mean of the reference interval (RI). We compared the 
      performance of these two approaches in women treated with raloxifene. METHODS: 
      Fifty postmenopausal osteopenic women (age 51-72 years) were randomised to 
      raloxifene or no treatment for 2 years. Blood samples were collected for the 
      measurement of BTM. The LSC for each marker was calculated from the untreated 
      women and the RI obtained from healthy premenopausal women (age 35-40 years). 
      Bone mineral density (BMD) was measured at the spine and hip. RESULTS: There was 
      a decrease in BTM in response to raloxifene treatment, percentage change at 
      12 weeks: C terminal telopeptide of type I collagen (CTX) -39 % (95 % CI -48 to 
      -28) and N terminal propeptide of type I procollagen (PINP) -32 % (95 % CI -40 to 
      -23) P < 0.001. The proportion of women classified as responding to treatment 
      using LSC at 12 weeks was as follows: CTX 38 % and PINP 52 % and at 48 weeks CTX 
      60 % and PINP 65 %. For the RI approach, the proportion of women classified as 
      responding to treatment at 12 weeks was CTX and PINP 38 % and at 48 weeks CTX 
      40 % and PINP 45 %. There was a significant difference in the change in spine BMD 
      in the raloxifene-treated group compared to the no-treatment group at week 48: 
      difference 0.031 g/cm(2) (95 % CI 0.016 to 0.046, P < 0.001). CONCLUSIONS: The 
      two approaches identified women that reached the target for treatment using BTM. 
      Both LSC and RI criteria appear useful in identifying treatment response, but the 
      two approaches do not fully overlap and may be complementary.
FAU - Naylor, K E
AU  - Naylor KE
AD  - Academic Unit of Bone Metabolism, The Mellanby Centre for Bone Research, 
      University of Sheffield, Sheffield, UK. k.e.naylor@sheffield.ac.uk.
FAU - Jacques, R M
AU  - Jacques RM
AD  - School of Health and Related Research, University of Sheffield, Sheffield, UK.
FAU - Peel, N F A
AU  - Peel NF
AD  - Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Northern General Hospital Sheffield, Sheffield, UK.
FAU - Gossiel, F
AU  - Gossiel F
AD  - Academic Unit of Bone Metabolism, The Mellanby Centre for Bone Research, 
      University of Sheffield, Sheffield, UK.
FAU - Eastell, R
AU  - Eastell R
AD  - Academic Unit of Bone Metabolism, The Mellanby Centre for Bone Research, 
      University of Sheffield, Sheffield, UK.
LA  - eng
GR  - MR/K006312/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160330
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation 
      between the European Foundation for Osteoporosis and the National Osteoporosis 
      Foundation of the USA
JID - 9100105
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type I)
RN  - 0 (Procollagen)
RN  - 4F86W47BR6 (Raloxifene Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - *Bone Density
MH  - Bone Diseases, Metabolic/*drug therapy
MH  - *Bone Remodeling
MH  - Collagen Type I/blood
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/*drug therapy
MH  - Postmenopause
MH  - Procollagen/blood
MH  - Raloxifene Hydrochloride/*therapeutic use
OTO - NOTNLM
OT  - Bone markers
OT  - Bone resorption
OT  - Osteopenia
OT  - Raloxifene
EDAT- 2016/03/31 06:00
MHDA- 2018/03/23 06:00
CRDT- 2016/03/31 06:00
PHST- 2015/11/25 00:00 [received]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/03/31 06:00 [entrez]
PHST- 2016/03/31 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
AID - 10.1007/s00198-016-3573-z [pii]
AID - 10.1007/s00198-016-3573-z [doi]
PST - ppublish
SO  - Osteoporos Int. 2016 Aug;27(8):2585-92. doi: 10.1007/s00198-016-3573-z. Epub 2016 
      Mar 30.